Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2014-10-27 AGM Information
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Presentation to Shareholders at AGM 2014 24 pages 3.5MB
AGM Information Classification · 95% confidence The document is titled '2014 AGM Presentation' and includes an agenda typical for an Annual General Meeting presentation, such as significant achievements, financial highlights, product pipeline updates, and strategic imperatives. It contains forward-looking statements and detailed business updates but does not present a full annual report or detailed financial statements. The length (15,000 characters) and content indicate it is a presentation document rather than a formal report or announcement. Therefore, it fits the category of AGM Information (AGM-R).
2014-10-27 English
Results of Annual General Meeting 2 pages 495.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'ASX Announcement' and specifically states 'Regeneus results of Annual General Meeting' and provides detailed voting results for resolutions passed at the AGM held on 28 October 2014. It references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. The content is focused on the announcement of the voting outcomes rather than the full AGM materials or minutes. The document length is 6875 characters, which is sufficient to include detailed voting results but not a full AGM report or presentation. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcement (DVA).
2014-10-27 English
Response to 7.30 media commentary 4 pages 234.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 October 2014 from Regeneus Ltd responding to media commentary on a previous ASX release dated 27 August 2014. It addresses allegations of misleading information regarding clinical trial results and regulatory approvals. The content is a detailed company statement clarifying and defending its prior disclosures rather than presenting new financial data or comprehensive financial results. It does not contain financial statements, earnings highlights, or management discussion of financial performance. It is not a report publication announcement since it is substantive and lengthy (over 12,000 characters) and is not merely stating that a report is attached or published elsewhere. The document is a regulatory announcement responding to external media claims and clarifying company disclosures, fitting best under Regulatory Filings (RNS).
2014-10-08 English
Trading Halt 2 pages 142.6KB
Regulatory Filings Classification · 100% confidence The document is a market release dated 7 October 2014 from Regeneus Ltd announcing a trading halt of its securities on the ASX. The text explains the reason for the trading halt is to allow the company to consider and respond to media commentary related to its stem cell therapy. There is no financial data, no report attached or referenced as being published, and no detailed financial or management information. The document is a regulatory announcement about trading status, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2014-10-06 English
RGS receives R&D tax incentive refund of $3.7m 1 pa
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement about Regeneus receiving a $3.7 million R&D tax incentive refund for activities conducted during the 2014 financial year. It describes the use of funds and provides company background information. The document is short (2248 characters) and does not contain financial statements or detailed financial analysis. It is an announcement of a financing-related event (receipt of government funds) rather than a full financial report or detailed capital structure update. Given the nature of the announcement about receiving funds related to R&D tax incentives, it fits best under Capital/Financing Update (CAP).
2014-09-24 English
Notice of Annual General Meeting/Proxy Form 18 pages 4.1MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting' and includes detailed information about the AGM scheduled for 28 October 2014. It contains the Notice of Meeting, Explanatory Statement, resolutions to be voted on at the AGM, voting exclusion statements, and procedural details for attendance and proxy voting. The document references the financial report, directors' report, auditor's report, and remuneration report as items to be received or adopted at the meeting, but does not itself contain these reports. The content is consistent with materials typically provided to shareholders ahead of an AGM to inform them of the meeting agenda and resolutions. Therefore, this document is the AGM Information, not the actual Annual Report or other filings. The length (15,000 characters) and detailed meeting information confirm it is not a brief announcement or proxy statement but the AGM notice and explanatory materials.
2014-09-24 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.